In this week's edition, a Labcorp blood test identifies signs of neurodegenerative disease; the FDA approves an oral treatment for partial seizures in teens; ketamine shows efficacy in epilepsy; and more. Read the full coverage here: Labcorp blood test identifies signs of neurodegenerative disease FDA approves oral treatment for partial seizures in patients aged 16 years and older Ketamine effective treatment for neonatal, pediatric epilepsy FDA places hold on phase 2/3 clinical trial of stroke therapy Hypertension, obesity, physical inactivity among highest risk factors for dementia References: Jacobwitz M, et al. Neurology. 2022;doi:10.1212/WNL.0000000000200889. Lee M, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.19672. Press Release Press Release Press Release

Ver todos los episodios